McKesson posted adjusted earnings per share of $8.03 for the quarter ended December 31, 2024, missing the analyst consensus of $8.27. Revenue came in at $95.29 billion, up 18% YoY but below the ...

Conventum – Alluvium Global Fund stated the following regarding McKesson Corporation (NYSE:MCK) in its Q3 2024 investor letter: "McKesson Corporation (NYSE:MCK), the drug distributor ...

Through its Precision Care Companion, McKesson wants to help oncologists bring personalized medicine to their patients ...

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and ...

McKesson Corporation (NYSE:MCK) is a Texas-based healthcare company that specializes in pharmaceutical distribution and offers health information technology, medical supplies, and health ...

During fiscal Q3 2025, McKesson Corporation (NYSE:MCK) reported revenue of $95.3 billion—an 18% increase compared to the same quarter last year. Adjusted operating profit also climbed 16% to $1. ...

A significant trading signal occurred for McKesson, as it demonstrated a Power Inflow at $687.38, after which MCK rose up to 0.8%. Over the last three years, diversification has fallen out of fashion.

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and ...